ASHP
Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›
The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed. Read More ›
Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results. Read More ›